Synthetic Joint Lubricant Could Treat Osteoarthritis
Engineers developed a material that mimics natural joint function and is now advancing toward human clinical trials.
Updated on Oct. 24, 2026 in Arthritis

Live Poll
Would you participate in an early-stage human clinical trial for a new arthritis treatment?
Cornell University engineers have developed a synthetic joint lubricant designed to mimic natural lubricin for the treatment of osteoarthritis. The material, which is currently moving toward human trials in Australia, aims to offer a more scalable solution for the more than 500 million people worldwide living with the condition.
Why it matters
Managing osteoarthritis is challenging because producing natural lubricin in large, effective quantities remains difficult and costly. This synthetic alternative could eventually provide a more accessible way to reduce joint friction and support long-term mobility for those affected by cartilage degradation.
A 2019 laboratory study utilizing cow cartilage demonstrated that the synthetic polymer significantly reduced friction, bringing the coefficient from 0.39 down to 0.09. These results are considered preliminary as researchers prepare for upcoming human trials.
The players
David Putnam
A researcher at Cornell University who led the multi-decade development of the synthetic lubricant.
Lawrence Bonassar
A Cornell University researcher who co-led the development team for the synthetic joint material.
Pleryon Therapeutics
A startup company founded to commercialize synthetic joint lubricant technology.
Zhexun Sun
The chief technology officer of Pleryon Therapeutics and a former student involved in the research.
The details
The synthetic material is engineered as a polymer featuring two distinct functional sections: one designed to anchor to joint tissue and another to retain a protective layer of water. This structure creates a thin, slippery interface on the surface of the cartilage. By maintaining this hydration layer, the polymer effectively mimics the role of natural lubricin to minimize mechanical wear and friction within the joint.
Timeline
2019: A laboratory study was conducted using cow cartilage.
2020: A follow-up study on the effectiveness of the polymer structure was published.
Health Landscape
This development represents a departure from traditional therapies by focusing on synthetic biomimicry to address the mechanics of osteoarthritis. It builds upon a decade of research at Cornell University aimed at overcoming the production hurdles associated with natural joint proteins.
While this technology is an early-stage development, it offers a new avenue for those managing knee pain to track as it progresses toward human clinical trials. Any questions regarding current treatments or new therapeutic options should be discussed with a qualified rheumatologist or orthopedic specialist.
The takeaway
Synthetic lubricants represent a promising strategy for managing joint health by reducing surface friction, a process that is currently being evaluated for its viability in human patients. Keep an eye on ongoing clinical trial announcements to see how this technology evolves for potential future use.
Further reading
Learn more about the latest innovations in joint care in our Arthritis section.
Source note: This article includes information reported by JagranJosh India.
Live Poll
Would you participate in an early-stage human clinical trial for a new arthritis treatment?





